Caisse DE Depot ET Placement DU Quebec Has $163.69 Million Stock Holdings in Boston Scientific Co. (NYSE:BSX)

Caisse DE Depot ET Placement DU Quebec raised its stake in Boston Scientific Co. (NYSE:BSX - Free Report) by 7.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,832,594 shares of the medical equipment provider's stock after purchasing an additional 126,837 shares during the period. Caisse DE Depot ET Placement DU Quebec owned about 0.12% of Boston Scientific worth $163,687,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently added to or reduced their stakes in the company. Mechanics Bank Trust Department purchased a new stake in shares of Boston Scientific during the 4th quarter worth approximately $415,000. Highland Capital Management LLC acquired a new position in Boston Scientific in the fourth quarter valued at $4,887,000. Covenant Asset Management LLC purchased a new stake in Boston Scientific in the fourth quarter valued at approximately $3,405,000. Brookstone Capital Management raised its position in Boston Scientific by 23.7% in the 4th quarter. Brookstone Capital Management now owns 105,860 shares of the medical equipment provider's stock valued at $9,455,000 after purchasing an additional 20,307 shares during the last quarter. Finally, Beacon Investment Advisory Services Inc. grew its holdings in shares of Boston Scientific by 31.7% during the fourth quarter. Beacon Investment Advisory Services Inc. now owns 19,527 shares of the medical equipment provider's stock worth $1,744,000 after buying an additional 4,702 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company's stock.

Insider Buying and Selling at Boston Scientific

In related news, CEO Michael F. Mahoney sold 164,443 shares of the business's stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $102.48, for a total value of $16,852,118.64. Following the completion of the sale, the chief executive officer now owns 1,535,706 shares of the company's stock, valued at approximately $157,379,150.88. The trade was a 9.67 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Arthur C. Butcher sold 17,314 shares of the stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $102.06, for a total transaction of $1,767,066.84. Following the transaction, the executive vice president now owns 22,235 shares in the company, valued at approximately $2,269,304.10. This trade represents a 43.78 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 302,453 shares of company stock worth $31,264,103 over the last 90 days. Insiders own 0.50% of the company's stock.

Boston Scientific Trading Down 0.3 %

Shares of NYSE BSX traded down $0.31 on Tuesday, reaching $103.94. 1,375,118 shares of the company traded hands, compared to its average volume of 7,804,323. Boston Scientific Co. has a fifty-two week low of $71.88 and a fifty-two week high of $107.17. The company has a 50 day moving average of $98.64 and a 200 day moving average of $95.60. The stock has a market capitalization of $153.73 billion, a PE ratio of 83.15, a P/E/G ratio of 2.79 and a beta of 0.68. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts' consensus estimates of $0.67 by $0.08. The firm had revenue of $4.66 billion during the quarter, compared to analysts' expectations of $4.57 billion. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. The firm's revenue was up 20.9% on a year-over-year basis. During the same period in the prior year, the company earned $0.56 EPS. On average, equities research analysts forecast that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

Analysts Set New Price Targets

BSX has been the subject of several analyst reports. Truist Financial increased their price target on Boston Scientific from $113.00 to $117.00 and gave the stock a "buy" rating in a report on Thursday, April 24th. UBS Group lifted their price target on Boston Scientific from $105.00 to $130.00 and gave the company a "buy" rating in a research note on Friday, February 7th. BTIG Research reiterated a "buy" rating and issued a $124.00 price objective on shares of Boston Scientific in a research report on Wednesday, April 23rd. Needham & Company LLC boosted their target price on shares of Boston Scientific from $113.00 to $115.00 and gave the stock a "buy" rating in a research report on Thursday, April 24th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Boston Scientific from a "hold" rating to a "buy" rating and set a $108.00 price target for the company in a report on Friday, January 10th. Twenty-three analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $114.52.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.